Caribou Biosciences halts vispa-cel and CB-011 CAR-T programs, cuts workforce, explores strategic alternatives

Caribou Biosciences, Inc.

Board approved restructuring on Oct 2, 2026 with estimated charges of $15M-$19M: $10M-$11M severance/benefits and $5M-$8M to wind down the ANTLER and CaMMouflage phase 1 trials.
Majority of affected employees expected to depart in Q4 2026; Board formed a Transaction Committee and engaged Wedbush Securities Inc. as exclusive financial advisor for the strategic review.
CFO Sriram Ryali's employment terminates upon execution of a binding definitive agreement for a strategic alternative; treated as termination without cause with severance.
Cash, cash equivalents and marketable securities totaled $113.8M as of June 30, 2026; no timeline set for completing the strategic alternatives review.
Discontinued programs: vispa-cel for r/r B cell non-Hodgkin lymphoma (pivotal trial-ready, FDA-aligned phase 3 design, RMAT/Fast Track/Orphan designations) and CB-011 for r/r multiple myeloma.

item 2.05 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sriram Ryali

Chief Financial Officer

CRBU · Caribou Biosciences, Inc.

Filed: October 6, 2026, 4:07 PM ET

The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2, 2025, between the Company and Mr. Ryali (the “Ryali Employment Agreement”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.92

Sriram Ryali departed as Chief Financial Officer at Caribou Biosciences, Inc..

Action: terminate
Role: Chief Financial Officer

Exact text from the filing

The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2, 2025, between the Company and Mr. Ryali (the “Ryali Employment Agreement”).

View on SEC.gov

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-415559

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.